Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill -- Ignore unavailable to you. Want to Upgrade?

To: Goose94 who wrote (12391)	3/31/2015 7:49:03 AM
From: Goose94	Read Replies (2) \| Respond to of 203627

Convalo Health Int'l (CXV-V) March 31, '15 an acquisition-oriented company focused on rolling up the US addiction rehabilitation market, is pleased to announce that it has entered into an agreement with a syndicate of Underwriters led by Mackie Research Capital Corporation and including Beacon Securities Limited (the "Underwriters"), whereby the Underwriters will purchase, on a bought-deal basis, 18,750,000 units (the "Units") of Convalo at a price of $0.40 per Unit for gross proceeds to Convalo of $7,500,000 (the "Offering"). Each Unit will consist of one (1) common share (a "Common Share") in the capital of Convalo and one (1) warrant (a "Warrant") of Convalo. Each Warrant entitles the holder thereof to acquire one Common Share for an exercise price of $0.50 per Common Share for a period of 36 months following closing of the Offering (the "Closing"). The expiry date of the Warrants may be accelerated by Convalo at any time following the six-month anniversary of the Closing and prior to the expiry date of the Warrants if the volume-weighted average trading price of the Common Shares is greater than $0.60 for any 20 consecutive trading days. The Company has granted the Underwriters an option (the "Agent's Option") to increase the size of the Offering by up to an additional 15% of the total number of Units to be issued under the Offering, at any time on or before 48 hours prior to the Closing. The Offering is scheduled to close on or about the week of April 20, 2015 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The securities to be issued under the Offering will have a hold period of four months from the Closing. The net proceeds from the Offering will be used by Convalo for acquisition purposes and general working capital. In consideration for their services, the Underwriters will receive a cash commission of 5.0% of the gross proceeds of the Offering, and shall receive such number of compensation options exercisable into Units, as is equal to 5.0% of the Units issued pursuant to the Offering. About Convalo Convalo is an acquisition-oriented company focused on rolling up the US outpatient addiction rehabilitation market led by seasoned management with experience in both US healthcare acquisitions and healthcare service asset management. In May 2014, Convalo made its first acquisition of a small, local addiction rehabilitation center in Los Angeles. Since May, the business has operated under the brand name BLVD Centers ( www.blvdcenters.com) in a luxury Hollywood, California location. BLVD offers patients access to a wide range of services, including addictive and co-occurring disorders, helpful to the recovery process. In conjunction with the 12-Step approach, BLVD also offers supplemental insurance-reimbursed services catering to a variety of communities: gender specific, creatively-oriented, meditation/mindfulness, trauma and LGBT affirmative. Convalo Health International, Corp. Dennis Wilson Corporate Affairs investorinfo@convalohealth.com www.convalohealth.com